Literature DB >> 15578980

Recent advances in the understanding of HIV-1 Vpu accessory protein functions.

Julie Binette1, Eric A Cohen.   

Abstract

HIV-1 encodes a number of accessory proteins, which are not commonly found in other retroviruses. These proteins, which include Vif, Vpr, Vpu and Nef, act as multifunctional adapters capable of recruiting and modulating basic host cell processes to optimize wide-ranging aspects of viral replication. This review describes our current understanding of how the Vpu accessory protein functions to modulate HIV-1 particle release and CD4 receptor expression during HIV-1 infection and underlines the potential opportunities afforded by this viral protein for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578980     DOI: 10.2174/1568008043339695

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  10 in total

1.  Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.

Authors:  Gabriela Khoury; Gary Ewart; Carolyn Luscombe; Michelle Miller; John Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

2.  Specific VpU codon changes were significantly associated with gp120 V3 tropic signatures in HIV-1 B-subtype.

Authors:  Salvatore Dimonte; Muhammed Babakir-Mina; Stefano Aquaro; Carlo-Federico Perno
Journal:  Virol Sin       Date:  2012-12-28       Impact factor: 4.327

3.  Evidences for viral strain selection in late stages of HIV infection: an analysis of Vpu alleles.

Authors:  Marcos Vinícius Pereira Gondim; Joaquim Xavier da Silva; Francisco Prosdocimi; Eduardo Leonardecz-Neto; Octávio Luiz Franco; Enrique Roberto Argañaraz
Journal:  Protein J       Date:  2012-02       Impact factor: 2.371

4.  Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation.

Authors:  Amjad Hussain; Clement Wesley; Mohammad Khalid; Ashutosh Chaudhry; Shahid Jameel
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

5.  A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells.

Authors:  Carina Banning; Jörg Votteler; Dirk Hoffmann; Herwig Koppensteiner; Martin Warmer; Rudolph Reimer; Frank Kirchhoff; Ulrich Schubert; Joachim Hauber; Michael Schindler
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

6.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

7.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20

8.  Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.

Authors:  Michael Schindler; Devi Rajan; Carina Banning; Peter Wimmer; Herwig Koppensteiner; Alicja Iwanski; Anke Specht; Daniel Sauter; Thomas Dobner; Frank Kirchhoff
Journal:  Retrovirology       Date:  2010-01-15       Impact factor: 4.602

9.  HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.

Authors:  Jean-Philippe Belzile; Ghislaine Duisit; Nicole Rougeau; Johanne Mercier; Andrés Finzi; Eric A Cohen
Journal:  PLoS Pathog       Date:  2007-07       Impact factor: 6.823

10.  Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum.

Authors:  Julie Binette; Mathieu Dubé; Johanne Mercier; Dalia Halawani; Martin Latterich; Eric A Cohen
Journal:  Retrovirology       Date:  2007-10-15       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.